The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Open accessAbstract
Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614
Self-citationMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 2×
“…of the receptors, fatty acid endogenous ligands, such as anandamide and 2-arachidonoyl glycerol (2-AG), and a degradation system including a re-uptake mechanism and hydrolytic enzymes have been identi®ed (Devane et al., 1992; Deutsch and Chin, 1993; Mechoulam et al., 1995; Dinh et al., 2002).”
BackgroundInfluentialInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Without the use of tissue-speci®c CB1 conditional knockouts (Marsicano et al., 2002), it is probably not possible to completely exclude some in¯uence of cannabinoid inhibition of the immune response in the neurodegenerative process.”
Method
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Lyman et al. (1989) examined the effects of parenteral THC in experimental autoimmune encephalomyelitis (EAE) in rats, a laboratory model of MS. THC treatment not only reduced CNS inflammation and improved neurological outcome but also improved survival compared with placebo.”
BackgroundInfluentialExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Inflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550
Self-citationYiangou, Y., Facer, P., Durrenberger, P., Chessell, I. P., Naylor, A., Bountra, C., Banati, R. R., & Anand, P. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-12 · Cited by 509
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03380.x · Cited by 482
A biosynthetic pathway for anandamide
Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., Chan, A. C., Zhou, Z., Huang, B. X., Kim, H.-Y., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601832103 · Cited by 470
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., Ledent, C., Cheng, X., Carrier, E. J., Mann, M. K., et al. (2007) · Nature Medicine · doi:10.1038/nm1561 · Cited by 363
Self-citationCannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362
Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
Kendall, D. A., & Yudowski, G. A. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00294 · Cited by 359
Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
Idris, A. I., van 't Hof, R. J., Greig, I. R., Ridge, S. A., Baker, D., Ross, R. A., & Ralston, S. H. (2005) · Nature Medicine · doi:10.1038/nm1255 · Cited by 356
“The strain of CB1 KO mice and wild type littermates used in this study were as described by Pryce and colleagues (23).”
MethodSelf-citationCannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
Cannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
Pharmacology of Medical Cannabis
Amin, M. R., & Ali, D. W. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-21737-2_8 · Cited by 278
Cannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208
Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., et al. (2007) · Brain · doi:10.1093/brain/awm160 · Cited by 207
Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“, 2015a), it is hypothesized that these substances may limit progressive neurodegeneration in MS (Pryce et al., 2003; Jackson et al., 2005; Witting et al., 2006).”
InfluentialMatias, I., Wang, J. W., Moriello, A. S., Nieves, A., Woodward, D. F., & Di Marzo, V. (2006) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.08.002 · Cited by 89
Bernal-Chico, A., Canedo, M., Manterola, A., Victoria Sánchez-Gómez, M., Pérez-Samartín, A., Rodríguez-Puertas, R., Matute, C., & Mato, S. (2015) · Glia · doi:10.1002/glia.22742 · Cited by 87
Al-Izki, S., Pryce, G., O'Neill, J. K., Butter, C., Giovannoni, G., Amor, S., & Baker, D. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.09.001 · Cited by 73
Self-citationDe Chiara, V., Motta, C., Rossi, S., Studer, V., Barbieri, F., Lauro, D., Bernardi, G., & Centonze, D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.069 · Cited by 37
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Metadata
- Authors
- Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., Cuzner, M. L., & Baker, D.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-10
- Volume
- 126
- Issue
- 10
- Pages
- 2191-2202
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2165031951
- Cited by
- 342
- References
- 70
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.